...
首页> 外文期刊>Cell transplantation >Mesoangioblasts from facioscapulohumeral muscular dystrophy display in vivo a variable myogenic ability predictable by their in vitro behavior.
【24h】

Mesoangioblasts from facioscapulohumeral muscular dystrophy display in vivo a variable myogenic ability predictable by their in vitro behavior.

机译:来自面肩肱型肌营养不良症的中成血管细胞在体内表现出可通过其体外行为预测的可变的成肌能力。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Facioscapulohumeral muscular dystrophy (FSHD) is the third most frequent inherited myopathy. We previously demonstrated that mesoangioblasts can be efficiently isolated from FSHD muscles, although their differentiation ability into skeletal muscle was variably impaired. This correlates with overall disease severity and degree of histopathologic abnormalities, since mesoangioblasts from morphologically normal muscles did not show any myogenic differentiation block. The aim of our present study was to verify whether mesoangioblasts from differentially affected FSHD muscles reproduce in vivo the same differentiation ability shown in vitro by studying their capability to form new muscle fibers during muscle regeneration of experimentally damaged muscles. We show that a diverse ability of FSHD mesoangioblasts to engraft and differentiate into skeletal muscle of SCID mice is strictly related to the characteristics of the muscle of origin, closely replicating in vivo what was previously observed in vitro. Moreover, we demonstrate that mesoangioblasts obtained from severely affected muscles scarcely integrate into muscle fibers, remaining mainly localized in the connective tissue. This suggests a defective migration in response to chemoattractants released by damaged fibers, as indicated by cell migration assays in response to HMGB1 and very low levels of RAGE expression, along with a decreased ability to fuse or to appropriately trigger the myogenic program. Our study indicates that FSHD mesoangioblasts from unaffected muscles can be used as selective treatment to halt muscle degeneration in severely affected muscles, and suggests that pharmacological and molecular interventions aimed to ameliorate homing and engraftment of transplanted autologous mesoangioblasts may open the way to cell therapy for FSHD patients, without requiring immunosuppression or genetic correction in vitro.
机译:面肩肱肱肌营养不良(FSHD)是第三常见的遗传性肌病。我们先前证明,中成血管细胞可以有效地从FSHD肌肉中分离出来,尽管它们分化为骨骼肌的能力会受到不同程度的损害。这与总体疾病严重程度和组织病理学异常程度相关,因为形态正常肌肉的中成血管细胞未显示任何肌源性分化阻滞。我们本研究的目的是通过研究实验受损的肌肉在再生过程中形成新的肌肉纤维的能力,来验证来自受差异影响的FSHD肌肉的中成血管细胞是否能够在体内复制出与体外相同的分化能力。我们表明,FSHD中成血管细胞移植和分化为SCID小鼠骨骼肌的多种能力与起源肌肉的特征严格相关,在体内可复制以前在体外观察到的情况。此外,我们证明从严重受影响的肌肉中获得的成血管成纤维细胞几乎不整合到肌肉纤维中,而主要保留在结缔组织中。这表明对受损纤维释放的趋化因子的迁移有缺陷,如对HMGB1和非常低水平的RAGE表达的细胞迁移测定所表明的,融合或适当触发肌原性程序的能力降低。我们的研究表明,未受影响的肌肉中的FSHD中成血管细胞可以用作选择性治疗,以阻止严重受影响的肌肉中的肌肉变性,并建议旨在改善自体中成血管细胞归巢和植入的药理和分子干预措施可能为FSHD的细胞治疗开辟道路患者,无需进行免疫抑制或体外基因校正。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号